CDKN2A and leukemia: The CDKN2A/B gene controls the cell cycle through the P53-MDM pathway; thus, co-occurrence of CDKN2A/B deletions and TP53 deletions might enhance the aggressiveness of disease by strongly increasing the self-renewal capacity of leukemia cells (29–31).